Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-DURATION
NCT07450365Phase 4Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 4, randomised, open-label trial of ganciclovir and valganciclovir in congenital cytomegalovirus infection (cCMV) (2 arms). Primary endpoints: Composite Poor Neurodevelopmental Outcome at 12 months, Death at 12 months and 6 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ganciclovirvalganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT07450365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450365.